InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.083 0.005 (6.41%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Notice of Annual General Meeting and Proxy Form 14 Oct 2020 8:19AM $0.415 $0.083 fallen by 80%
$26 LuPIN Study Achieves Final Patient Treatment 12 Oct 2020 8:36AM $0.405 $0.083 fallen by 79.51%
$26 Noxopharm CMO Discusses the NOXCOVID trial 9 Oct 2020 12:42PM $0.390 $0.083 fallen by 78.72%
$26 Unlisted Options Expiring 27 November 2020 9 Oct 2020 8:41AM $0.395 $0.083 fallen by 78.99%
$26 Cleansing Notice 9 Oct 2020 8:37AM $0.395 $0.083 fallen by 78.99%
$26 Appendix 2A 9 Oct 2020 8:33AM $0.395 $0.083 fallen by 78.99%
$26 Noxopharm Loan Terms Amended to Benefit Company 6 Oct 2020 8:18AM $0.365 $0.083 fallen by 77.26%
$26 First COVID-19 Patient Treated in Veyonda Study 2 Oct 2020 8:28AM $0.390 $0.083 fallen by 78.72%
$26 Noxopharm Corporate Presentation September 2020 21 Sep 2020 9:07AM $0.390 $0.083 fallen by 78.72%
$26 Noxopharm Appoints US Corporate Advisory and Consulting Firm 18 Sep 2020 10:34AM $0.350 $0.083 fallen by 76.29%
$26 Notification of Date of 2020 Annual General Meeting 17 Sep 2020 9:19AM $0.350 $0.083 fallen by 76.29%
$26 Annual Report to shareholders 15 Sep 2020 8:42AM $0.310 $0.083 fallen by 73.23%
$26 Appendix 4G and Corporate Governance Statement 15 Sep 2020 8:37AM $0.310 $0.083 fallen by 73.23%
$26 Noxopharm Appoints New Chair 9 Sep 2020 8:21AM $0.295 $0.083 fallen by 71.86%
$26 Global CRO To Execute DARRT-2 Prostate Cancer Study 8 Sep 2020 8:17AM $0.315 $0.083 fallen by 73.65%
$26 Veyonda COVID-19 Study Approved For Immediate Start 1 Sep 2020 8:52AM $0.305 $0.083 fallen by 72.79%
$26 Final Director's Interest Notice - ID 31 Aug 2020 10:23AM $0.295 $0.083 fallen by 71.86%
$26 Appendix 4E and Audited Financial Statements FY2020 31 Aug 2020 10:20AM $0.295 $0.083 fallen by 71.86%
$26 Appendix 4G and Corporate Governance Statement 31 Aug 2020 10:15AM $0.295 $0.083 fallen by 71.86%
$26 Noxopharm Announces Board Changes 31 Aug 2020 8:38AM $0.300 $0.083 fallen by 72.33%
$26 Appendix 2A - Shares 14 Aug 2020 6:18PM $0.325 $0.083 fallen by 74.46%
$26 Cleansing Notice 14 Aug 2020 6:16PM $0.325 $0.083 fallen by 74.46%
$26 Appendix 2A - Underwriter Options 14 Aug 2020 6:14PM $0.325 $0.083 fallen by 74.46%
$26 Results of Meeting 14 Aug 2020 6:09PM $0.325 $0.083 fallen by 74.46%
$26 Noxopharm August 2020 EGM Corporate Presentation 14 Aug 2020 8:26AM $0.315 $0.083 fallen by 73.65%

351 - 375 of 794 results

Page 15 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.